Now Playing
|Videos|December 14, 2022
Coming Soon: Advances in Multiple Myeloma: Insights from Experts at the Moffit Cancer Center
Author(s)Melissa Alsina, MD
Melissa Alsina, MD, shares her excitement for an upcoming program wherein she and other key opinion leaders from the Moffit Cancer Center review updated data and optimal treatment strategies in the setting of multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma
5